1. Home
  2. CANF vs BOXL Comparison

CANF vs BOXL Comparison

Compare CANF & BOXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$0.31

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Logo Boxlight Corporation

BOXL

Boxlight Corporation

HOLD

Current Price

$0.81

Market Cap

5.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CANF
BOXL
Founded
1994
1985
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Telecommunications Equipment
Sector
Health Care
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
5.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
CANF
BOXL
Price
$0.31
$0.81
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$6.75
N/A
AVG Volume (30 Days)
19.5M
207.8K
Earning Date
11-27-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$560,000.00
$106,608,000.00
Revenue This Year
$461.72
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.73
52 Week High
$2.33
$10.65

Technical Indicators

Market Signals
Indicator
CANF
BOXL
Relative Strength Index (RSI) 34.84 34.90
Support Level $0.28 $0.81
Resistance Level $0.39 $0.95
Average True Range (ATR) 0.05 0.10
MACD 0.01 0.03
Stochastic Oscillator 9.85 21.92

Price Performance

Historical Comparison
CANF
BOXL

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

About BOXL Boxlight Corporation

Boxlight Corp is a technology company that develops, sells, and services interactive solutions predominantly for the education market but also for the corporate and government sectors. The company currently designs, produces, and distributes interactive technologies, including interactive and non-interactive flat panel displays, LED video walls, media players, classroom audio and campus communication, cameras, and other peripherals for the education market and non-interactive solutions including flat panels, LED video walls, and digital signage. The company also distributes science, technology, engineering, and math (or STEM) products, including 3D printing and robotics solutions and a portable science lab.

Share on Social Networks: